Stock Events

Stock Events

Biocryst Pharmaceuticals 

€7.71
152
-€0.17-2.11% Today

Statistics

Day High
7.71
Day Low
7.71
52W High
9.71
52W Low
5.28
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
0.04
0.34
0.65
0.95
Expected EPS
0.03777701513
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BO1.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Biocryst's focus on rare diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals competes in the rare disease space with its RNAi therapeutics, overlapping with Biocryst's target market.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is involved in developing and commercializing treatments for rare diseases, among other areas, making it a competitor.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences operates in the development of antiviral drugs for infections like HIV, hepatitis, and influenza, competing with Biocryst's antiviral programs.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including treatments for rare diseases, which puts it in competition with Biocryst.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, directly competing with Biocryst's rare disease portfolio.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk is a leading company in diabetes care but also ventures into rare blood disorders, making it a competitor in the rare disease market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad portfolio including treatments for rare diseases and a strong focus on research and development, competing across several of Biocryst's areas of interest.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a diverse biopharmaceutical portfolio, including treatments for rare diseases, competing with Biocryst in the biotech and pharmaceutical market.

About

There is no Profile data available for BO1.SG.
Show more...
CEO
Country
Germany
ISIN
US09058V1035

Listings

MU
DE
BO1.MU
STU
DE
BO1.STU
F
DE
BO1.F
XNAS
US
BCRX

0 Comments

Share your thoughts

FAQ

What is Biocryst Pharmaceuticals stock price today?▼
The current price of BO1.MU is €7.71 EUR — it has decreased by -2.11% in the past 24 hours. Watch Biocryst Pharmaceuticals stock price performance more closely on the chart.
What is Biocryst Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biocryst Pharmaceuticals stocks are traded under the ticker BO1.MU.
Is Biocryst Pharmaceuticals stock price growing?▼
BO1.MU stock has risen by +1.85% compared to the previous week, the month change is a -4.65% fall, over the last year Biocryst Pharmaceuticals has showed a -17.36% decrease.
In which sector is Biocryst Pharmaceuticals located?▼
Biocryst Pharmaceuticals operates in the Materials sector.
When did Biocryst Pharmaceuticals complete a stock split?▼
Biocryst Pharmaceuticals has not had any recent stock splits.